Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Queensland Health
US Army
Argus Health
McKesson
Harvard Business School
Cerilliant
Moodys
Chubb
Citi

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,323,677

« Back to Dashboard

Summary for Patent: 8,323,677
Title:Therapeutic foam
Abstract: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurized canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimizing the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.
Inventor(s): Wright; David Dakin Iorwerth (Buckinghamshire, GB), Harman; Anthony David (Oxfordshire, GB), Robinson; Nikki (Uxbridge, GB), Hodges; Garry (Middlesex, GB), Kadar; Adil (Middlesex, GB), Moggridge; Geoffrey D. (Cambridge, GB), Van Liew; Hugh (Bamstable, MA)
Assignee: BTG International Ltd. (London, GB)
Application Number:12/765,980
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 8,323,677

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,323,677

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0326768.9Nov 17, 2003
United Kingdom0422307.9Oct 7, 2004

Non-Orange Book US Patents Family Members for Patent 8,323,677

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,734,833 Therapeutic foam ➤ Sign Up
7,731,986 Therapeutic foam ➤ Sign Up
7,763,269 Therapeutic foam ➤ Sign Up
8,048,439 Therapeutic foam ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,323,677

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1701701 ➤ Sign Up
Slovenia 1694292 ➤ Sign Up
Russian Federation 2006121470 ➤ Sign Up
Russian Federation 2006121468 ➤ Sign Up
Russian Federation 2006121443 ➤ Sign Up
Portugal 1701701 ➤ Sign Up
Portugal 1694292 ➤ Sign Up
Poland 223344 ➤ Sign Up
Poland 380484 ➤ Sign Up
African Intellectual Property Organization (OAPI) 13287 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Julphar
AstraZeneca
Johnson and Johnson
Deloitte
Merck
Colorcon
Cerilliant
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot